Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna Inc (NQ: MRNA )

43.39 +1.34 (+3.19%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna Inc

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
99 100 Next >
Moderna's Options: A Look at What the Big Money is Thinking
Via Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth $900 Today
Via Benzinga
Market Whales and Their Recent Bets on MRNA Options
Via Benzinga
S&P 500, Nasdaq Lurking Below Record Highs
Stocks are scattered this afternoon, as investors digest a weaker-than-expected retail sales reading from May. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Covid-19 Pharma Stars Continue Their Quest To Set New Standards In Cancer Treatment
AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its blockbuster cancer drug Imfinzi combined with chemotherapy being used as a... 
Via Benzinga
Exposures COVID-19
The RBA Kept Interest Rates On Hold And Remained Hawkish
The Reserve Bank of Australia kept the cash rate at 4.35% at its June meeting, leaving borrowing costs unchanged for the fifth time. 
Via Talk Markets
Smart Money Is Betting Big In MRNA Options
Via Benzinga
Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine
Via ACCESSWIRE
OpenAI And Color Health Develop AI-Driven Cancer Care Solutions: Report
OpenAI and startup Color Health have developed an AI assistant, named 'copilot', to support physicians in creating personalized cancer care plans, emphasizing the tool's role in augmenting rather than... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Moderna Stock Soars on Cutting-Edge Personalized Cancer Vaccines
Biotechnology firm Moderna Inc. (NASDAQ: MRNA) made mainstream headlines during the pandemic for its COVID-19 vaccines. Moderna is focused on messenger RNA 
Via MarketBeat
Exposures COVID-19
Moderna Just Gave Investors Another Reason to Buy the Stock
The company's post-pandemic prospects are getting brighter. 
Via The Motley Fool
Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation COVID-19 Vaccine
Via ACCESSWIRE
7 Struggling Stocks to Sell Before July 2024
The stock market is riding high for now. But even a roaring bull market can't save these seven stocks to sell. 
Via InvestorPlace
3 Vaccine Stocks to Buy as the FDA Cracks Down on New Variants
After the FDA's authorization of a Covid19 booster shot, you may want to consider adding these vaccine stocks to your portfolio. 
Via InvestorPlace
Exposures Product Safety
Moderna, Inc. (MRNA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
What's Going On With Moderna Stock Monday?
Moderna said its Phase 3 trial of mRNA-1083, an investigational combination vaccine against influenza and COVID-19, met its primary endpoints. 
Via Benzinga
Exposures COVID-19
Nike, Merck, General Motors, And More: CNBC's 'Final Trades'
Liz Young of SoFi recommends Energy Select Sector SPDR Fund as her final trade on CNBC's Halftime Report. Jim Lebenthal of Cerity Partners picks General Motors, while Jason Snipe of Odyssey Capital... 
Via Benzinga
Moderna Says Combination Flu And Covid Vaccine Beat Out Rivals From Sanofi, GSK
If approved, this would be the first combination vaccine based on mRNA technology to hit the market. 
Via Investor's Business Daily
Exposures COVID-19
Why Moderna Stock Is a No-Brainer Buy Right Now
This messenger-RNA pioneer should be able to keep its rebound going. 
Via The Motley Fool
Moderna Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19
Via ACCESSWIRE
3 Reasons to Buy Moderna Stock
The biotech hasn't said its last word. 
Via The Motley Fool
Moderna Seeks FDA Approval For Updated COVID-19 Shot For Upcoming Season
Moderna has submitted an FDA application for its 2024-2025 Spikevax formula, targeting the prevalent SARS-CoV-2 variant JN.1. 
Via Benzinga
Exposures COVID-19 Product Safety
5 Stocks Propelling S&P 500 To 25th Record High
While most of the stocks have performed well, here are five of them that led the way higher in yesterday's trading session. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Meme Stocks Surge Led by ‘Roaring Kitty’ and Social Media Buzz on Reddit (NYSE: RDDT), GME, DYAI, AMC, PRSO, NVAX
Via AB Newswire
First Human Death From Bird Flu Strain Puts Vaccine Stocks Back On The Map
Moderna shares are up almost 29% this month; CureVac is up 72% in the past month; and Novavax spiked 317% in the past month. 
Via Benzinga
Novavax Stock’s Recent Surge and Future Potential
Novavax's future hinges on its ability to translate recent stock market momentum into sustained financial performance. 
Via MarketBeat
Topics Economy
Exposures COVID-19 Product Safety Supply Chain
FDA Selects Moderna's Rare Disease Candidate For Accelerated Development Program
Moderna's mRNA-370 has been selected for the FDA's START program to accelerate rare disease therapeutics, targeting a 2024 pivotal study. 
Via Benzinga
Exposures Product Safety
Is a Giant Short Squeeze Brewing in Novavax (NVAX) Stock?
Novavax will be ready for the new Covid-19 JN.1 variants in September, but NVAX stock is also undergoing a short squeeze. 
Via InvestorPlace
Exposures COVID-19
Novavax, With A 369% Gain, Tears Ahead Again On Key FDA Move
Novavax also said it's planning to launch a JN.1-focused Covid booster shot this fall. 
Via Investor's Business Daily
Exposures COVID-19 Product Safety
Dyadic International Inc. (NASDAQ: DYAI) Hits New 52-Week High Amidst Golden Cross, Bullish Swing Patterns and Bird Flu Concerns
Via AB Newswire
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.